A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Germ cell and embryonal neoplasms
- Focus Therapeutic Use
- 15 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 15 Feb 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.
- 10 Jun 2017 Biomarkers information updated